NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Novartis
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
Novartis